Sørensen P G, Nissen M H, Groth S, Rørth M
Cancer Chemother Pharmacol. 1985;14(3):247-9. doi: 10.1007/BF00258126.
To evaluate the value of beta-2-microglobulin as an indicator of acute and long-term cis-platinum-induced nephrotoxicity, 51Cr-EDTA clearance and serum concentration and urinary excretion of beta-2-microglobulin were measured in 18 patients treated with a regimen including cis-platinum. Before treatment all values were within the normal range. During treatment 51Cr-EDTA clearance decreased from 108 to 90 ml/min/1.73 m2 (P less than 0.02). The decrease was irreversible, while a transient 2 to 5-fold increase in beta-2-microglobulin excretion in the urine was seen during treatment. Serum beta-2-microglobulin remained unchanged. The decrease in 51Cr-EDTA clearance was not correlated to either the peak increase in the beta-2-microglobulin excretion or to the time of occurrence of the peak (R = 0.3). Thus, it is not possible to predict the long-term nephrotoxicity of cis-platinum by measuring the beta-2-microglobulin excretion during treatment.
为评估β2-微球蛋白作为顺铂诱导的急性和长期肾毒性指标的价值，对18例接受含顺铂方案治疗的患者测定了51Cr-EDTA清除率以及β2-微球蛋白的血清浓度和尿排泄量。治疗前所有值均在正常范围内。治疗期间，51Cr-EDTA清除率从108降至90 ml/min/1.73 m2（P<0.02）。这种降低是不可逆的，而治疗期间尿中β2-微球蛋白排泄量有短暂的2至5倍增加。血清β2-微球蛋白保持不变。51Cr-EDTA清除率的降低与β2-微球蛋白排泄量的峰值增加或峰值出现时间均无相关性（R=0.3）。因此，在治疗期间通过测量β2-微球蛋白排泄量无法预测顺铂的长期肾毒性。
